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Fibroblast growth factors (FGFs) lack signal sequences, and are exported through
endoplasmic reticulum (ER)-Golgi-independent non-classical routes. FGFs work as
modulators of various cellular activities like mitosis, differentiation, survival etc.
Among the FGF family, which comprises of 23 different heparin proteins, human FGF-1
(hFGF-1), a potent angiogenic factors are one of the targets in cancer inhibition, as they
are involved in blood vessel formation in tissues. There has been intensive research
directed at the development of drugs that could effectively inhibit angiogenesis. In this
context, the purpose of this study is to fully understand the molecular principles essential
to determine probability of inhibition of hFGF-1 signaling transduction by imatinib.
Imatinib, a 2-phenyl amino pyrimidine derivative is a tyrosine kinase inhibitor with
antineoplastic activity. Imatinib binds to the intracellular pocket located within tyrosine
kinases and inhibit the downstream cell proliferation events, but the exact molecular
mechanism is still elusive. In this study, expression of hFGF-1 in recombinant E. coli
was carried out, and the expressed protein was purified using heparin affinity column
chromatography. The structural interactions governing imatinib-hFGF-1 interaction was
studied by monitoring its stability, conformation and binding affinity by equilibrium
unfolding using steady state fluorescence and proteolytic digestion assay. These data
show that imatinib binds to hFGF-1 and enhances its thermal stability and solvent
accessibility. In addition, biacore analysis was carried out to determine the binding
affinity of imatinib to hFGF-1.
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1. INTRODUCTION
1.1.

Protein Export

Protein transport across the ER membrane in eukaryotes is an early and decisive step
in the biosynthesis of many proteins [1]. Proteins, which are produced by the cell, must
reach their correct locations for the cell to function properly. Proteins which are
synthesized in the cell need to be delivered to the proper targeting (or) protein sorting
encompasses two very different kind of process [2].
Targeting of water soluble protein occurs through the translocation of the protein
across the membrane into the aqueous organelle. In the case of membrane proteins,
targeting leads to insertion of the protein into the lipid bilayer of the membrane [2]. In
the second step, which is the primary sorting process, proteins are sorted to the
endoplasmic reticulum (ER), mitochondria, chloroplast, peroxisomes and the nuclease.
Both types of proteins (soluble and membrane proteins) use the same machinery for
translocation across the membrane, a protein-conducting channel with hydrophilic
interior. This channel, in contrast to those channels that transport ions and small
molecules, has the unusual property of being able to open in two orientations;
perpendicular to the plane of the membrane to allow a polypeptide segment across, and
within, the membrane to allow a hydrophobic transmembrane segment of a membrane
protein to exit laterally into the lipid phase [3,4,5].

1

Figure 1: Sortning of nuclear-encoded proteins in eukaryotic cells.
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1.2.

Signal Sequence-Less Proteins

Proteins destined for the classical secretion pathway (e.g. serum proteins such as
immunoglobulins) typically contain N-terminal signal peptides that mediate membrane
translocation into the lumen of the endoplasmic reticulum followed by the ER/Golgidependent transport to the cell surface [2]. By contrast, a large group of exported
proteins do not have signal peptide [5].
The ability of these signal sequence-less proteins to undergo non-classical release
attracted considerate attention since they play roles in important physiological processes
such as cell growth and differentiation, inflammation and angiogenesis [6]. Among
those are important disease related proteins such as interleukin 1α and 1β, fibroblast
growth factors (FGF) 1 and 2, infection-related cell surface markers of Leishmania
parasites (HASP family), viral proteins such as Herpes simplex tegument protein vp22,
etc. Consistently, these secretory proteins do not localize to the endoplasmic reticulum
or the Golgi apparatus, and do not contain ER/Golgi-specific post-translational
modification such as glycosylation. Importantly, inhibitors of the classical pathway
including brefeldin A do not interfere with secretion of these proteins [7] (Fig.1).

1.3.

Non-classical export of hFGF-1

Human fibroblast growth factor-1 (hFGF-1) is a prototypical member of the FGF
family. Four kinase transmembrane receptors (FGFR1-4) and cell surface heparin sulfate
proteoglycans mediate FGFs biological effects. Most members of the family therefore
possess classical signal sequence but hFGF-1 and hFGF-2 do not have such sequences
and thus are released by a novel secretory mechanism. The existence of hFGF-1 and
3

hFGF-2–specific secretion pathways might represent a protective mechanism developed
in the course of evolution, which might be related to their high mitogenic potential and
widespread expression [8].
hFGF-1, a close relative of hFGF-2, is believed to be secreted by a mechanism
distinct from hFGF-2 export. hFGF-1 release can be triggered under stress condition
such as heat shock treatment, an experimental condition without any impact on hFGF-2
export [10, 11, 12] (Fig. 2).

4

Figure 2: Proposed mechanism for the non-classical release of hFGF-1. Two
intracellular proteins, S100A13 and Syt1 have been shown to associate with the latent
hFGF-1 homodimer in in the cytoplasm. Both S100A13 and p40-Syt1 are calcium
binding proteins and they are exported together with hFGF-1.
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Prudovsky et al., employing a real-time analysis of various hFGF-1-expressing
cell lines, have demonstrated that heat shock treatment triggers the redistribution of
hFGF-1 along with other components of the S100 release complex forming a diffuse
cytoplasmic pattern into a population that accumulates at the inner leaflet of the plasma
membrane [13,14]. This subcellular redistribution of hFGF-1 along with other
components of the release complex has been interpreted as the initial step of heat shocktriggered hFGF-1 secretion. Even though it remains elusive as to how the hFGF-1
containing hetero-oligomeric complex gets translocated across the plasma membrane,
the data clearly suggests that the overall process of hFGF-1 secretion does not involve
intracellular vesicles but rather relies on a direct transport mechanism at the level of the
plasma membrane [5,10].

1.4.

The Function and Structure of FGFs

FGFs are essential signaling molecules for the regulation of a variety of
physiological processes including embryonic growth, development, cell proliferation,
differentiation and angiogenesis [11,12]. FGFs are believed to elicit the biological
response by binding to two classes of receptors on the cell surface [13–15]. One
comprises of transmembrane receptor with intrinsic protein kinase activity. The second
class of receptors includes a family of cell surface heparan sulfate proteoglycans
(HSPG) that bind FGF with low affinity [16–18]. There is a lot of debate on the role of
the low affinity cell surface receptors in the FGF-mediated biological activities. A dual
receptor model for FGF action has been proposed in which it is suggested that binding
of heparin-like proteoglycans induces FGF oligomerization, which is crucial for
subsequent binding of the growth factor to the high affinity receptor(s) [19]. However,
6

several recent studies have indicated that heparin binding may not be mandatory for the
cell proliferation activity of FGFs [20–22].
The FGF family consists of at least 22 related members that have been identified
(FGF1-FGF22). These proteins share a common core of around 140 amino acids. The
amino acid sequences of FGFs isolated from various sources are well conserved. 28
residues are highly conserved and 6 residues are invariant [23]. 10 of the highly
conserved residues are involved in FGF receptor binding [13]. Acidic FGF (hFGF-1)
and basic FGF (hFGF-2) are considered prototypes of the whole family [13,24,25]. Fulllength FGF-1 and FGF-2 contain about 154 amino acids and they lack disulfide bonds
[9,13]. Both hFGF-1 and hFGF-2 contain a nuclear localization sequence (NLS) located
near the amino-terminus of the proteins [26–32]. However, the function of NLS
sequence in the FGF prototypes appears to be restricted since the initiation of translation
at the AUG start sites yield proteins which remain associated in the cytosol [26,27]. This
aspect is critical for the activity of the FGF prototypes as exogenous protein, since it is
unlikely that the nuclear-associated FGF can be expected to participate in a pathway of
secretions. The NLS sequences play a crucial role in maintaining the structural integrity
of FGF-1 that is required for optimal binding to and activation of its cell surface receptor
[32].
The first 23 N-terminal residues do not play any significant role in the cell
proliferation activity of hFGF-1 [13,33]. No significant differences in stability and
biological properties have been detected among the different truncated forms of FGF-1
[33]. However, deletion of residues 23 to 26 (Lys-Lys-Pro-Lys), plus replacing the
highly conserved residues of Leu27 by Met increases the heparin binding affinity and
7

ability to trigger early mitogenic events such as intracellular receptor-mediated tyrosine
phosphorylation but fails to induce DNA synthesis and cell proliferation [32]. As the
Lys-Lys-Pro-Lys-sequence bears similarity to the NLS sequence (NYKKPKL), it was
proposed that this stretch of residues (23-26) could be partly responsible for the
translocation of the receptor protein (FGFR) to the nucleus [32].
The 3-D structures of FGFs are available [12,34–36]. All these proteins form a trefoil structure with a pseudo 3-fold-axis of symmetry. The crystal and solution
structures of hFGF-1 have been determined at high resolution. Both results indicate that
hFGF-1 is an all -sheet protein consisting of 12 -strands arranged into a -trefoil
architecture [12,33–35,37]. 10 of the -strands are paired to form hairpin structures (straind II- -straind III, -straind IV- -straind V, -straind VI- -straind VII, -straind
VIII- -straind IX, -straind X- -straind XI). The -trefoil structure contains 4 stranded
-sheets in which -strand X and -strand XI forms the heparin-binding site (Fig. 3).
Recent NMR studies revealed that the residues 120-142, constitute the primary heparinbinding site in hFGF-1 [36,38]. Heparin binding regions are different then the FGFR
binding sites.

8

Figure 3: Three-dimensional structure of hFGF-1. The protein is bereft of disulfide
bonds (PDB access code IRG8).
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1.5.

FGFs and Heparin Binding

The binding interactions between FGFs and heparan sulfate proteoglycans were
found on the cell surface and in the extracellular matrix [39]. Owing to the strong
affinity of FGFs for heparin, it is believed that the glycosaminoglycan has a
physiological role [40]. Binding to heparin is shown to stabilize FGFs and thereby
diminishing their inactivation by heat, acid [41,42], proteolysis [43,44] and mild
oxidation in vitro [45]. Stabilization is particularly relevant for hFGF-1, which is shown
to exhibit an unfolding transition at physiological temperatures in the absence of
polyanions, such as heparin [42,42]. The heparin polymer is generated from disaccharide
repeat units consisting of D-glucosamine and L-iduronic acid joined by 1-4 linkages
[46,47] (Fig. 4). A minimal saccharide sequence required for hFGF-2 binding consists of
five monosaccharide units, with N-sulfate groups, and a single iduronic acid with 2-Osulfate residue but no 6-O-sulfate. However, by contrast, a sequence of about twice this
size is required to promote FGF-2- induced DNA synthesis [48].
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Figure 4: Structure and prevalent sequences in regular regions of heparin composed by
repeating disaccharide unit of D-glucosamine and uronic acid linked by 1-4
interglycosidic bond.
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X-ray and NMR structures of FGFs in the presence of the structural analogues of
heparin revealed that the glycosaminoglycan binding site is located in the C-terminal
region spanning residues 130-154 [34,35].

1.6.

FGF Receptor(s) – FGF Interaction(s)

The diverse activities of FGFs are mediated by binding to high-affinity receptor
tyrosine kinases [49]. The FGF receptor family comprises 4 transmembrane tyrosine
receptors (FGFR1-FGFR4), which have been identified in humans [50–53]. Each of
FGF receptor contains an extracellular ligand-binding region, a transmembrane helix
domain, and an intracellular tyrosine kinase domain including a catalytic site and an
ATP binding site [23,49,54] (Fig. 5). The homologies of human FGFR1- FGFR4 are in
the range of 54-69% [55,56]. The tyrosine kinase domains are the most conserved
regions. The ligand-binding region consists of domains (D1, D2 and D3).
Between D1 and D2 domain there is a stretch of positively charged amino acids
(called acid box, AB) [50,51,57]. Site-directed mutagensis studies and the recent crystal
structure data on the FGF-receptor complex have helped in the characterization of the
ligand (FGF)-receptor (FGFR) interface [23,49,54,58–60]. The C-terminal region of the
D3 domain has been shown to be important for ligand binding specificity [59].
Dimerization of the extracellular domains leads trans-autophosphorylation on
tyrosine residues. Phosphorylation of the tyrosine residues in the receptor either
activates the intrinsic catalytic activity of the receptor or results in the recruitment of
other downstream signaling proteins [61] (Fig. 6).
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Figure 5: Schematic of FGFR. The receptor is composed of three main portions: the
extracellular portion, a transmembrane domain, and a cytoplasmic tyrosine kinase
domain. The extracellular ligand-binding contains three domains. The tyrosine kinase
domain comprises an ATP binding site and a catalytic site inside the cell.
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Figure 6: Schematic representation of the mechanism of signal transduction induced by
hFGF-1. hFGF-1 binds to the extracellular (D2 and D3) domains of FGFR and induces
dimerization of hFGF-1 monomers. Dimerization of receptor monomers upon ligand
(FGFs) binding is likely to be a requisite for activation of the kinase domains, leading to
receptor transphosphorlation and then signal transduction.
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1.7.

hFGF-1 and Imatinib Interaction

Different mechanisms are proposed for hFGF-1 receptor dimerization. However,
models indicate that the D2 domains of FGF receptors are indispensable for the binding
interactions to hFGF-1 and heparin molecules. Tyrosine kinase plays an important role
in phosphate group transfer in a cell and also acts as a “on” and “off” switch in many
cellular processes. Kinases can be in “on” positions and trigger unregulated growth of
the cell which leads to cancer [62,63].
Imatinib, a kinase inhibitor (Fig. 7) was one of the first cancer therapies to show
potential for targeted action, and is often cited as a paradigm for research in cancer
therapeutics [64]. Imatinib is currently used to treat Philadelphia chromosome-positive
chronic myelogenous leukemia (Ph+ CML), gastrointestinal stromal tumors, and a
number of other malignancies [65,66]. Cancer development is facilitated via a signaling
cascade that begins with a phosphorylation event of subsequent proteins by BCR-Abl (a
tyrosine kinase enzyme). Imatinib works by inhibiting BCR-Abl, thus preventing
proliferation of cancer cells leading to their deaths by apoptosis [65,66]. Though
imatinib is known to be a tyrosine kinase inhibitor, its exact mechanism of action is still
elusive.

15

Figure 7: Represents the structure of imatinib, a tyrosine kinase inhibitor.

Since hFGF-1 mediated angiogenesis plays a crucial role in the progression and
metastasis of cancer, there has been an intensive research directed at the development of
drugs that could effectively inhibit angiogenesis. In this context, an attempt was made to
understand the molecular interaction between imatinib with growth factor.

The

structural interactions governing imatinib-hFGF-1 interaction were studied by
investigating its stability, conformation and binding affinity using steady state
fluorescence, proteolytic digestion assay and biacore respectively. Furthermore, the
proposed research will shed light on the potential role of imatinib in growth factor
induced angiogenesis.

16

2. MATERIALS AND METHODS
2.1. Materials
Reagent
Ammonium Sulfate
Ampicillin
ß-mercatoethanol
Chloramphenicol
CM5 chip
Disodium hydrogen
phosphate
E. coli [BL21(DE3)] pLysS
Glycerol
HBS-EP buffer (pH 7.4)
Heparin sepharose resin
Imatinib mesylate
Isopropyl β-D-1thiogalactopyranoside (IPTG)
L.B Media
SDS
Sodium Chloride
Sodium dihydrogen
phosphate
2,4,6Trichloroanisole (TCA)
Urea

Catalog number
AX1385-1
0339
M3148
C0378
BR-100399

Company
EMD Chemicals
Amresco
Sigma Aldrich
Sigma Aldrich
GE Healthcare

1.06573.0503

EMD Chemicals

C6000-03
GX0185-6
BR100188
17-0998-01
SML 1027

Invitrogen
EMD Chemicals
GE Healthcare
GE Healthcare
Sigma Aldrich

5820

Amresco

71753-6
7910
3624-05

Novagen
EMD Chemicals
J.T. Baker

SX0711-1

EMD Chemicals

T6399

Sigma Aldrich

4204-05

J.T. Baker

Table 1: List of all the supplies required for the study with their respective catalog
number and manufacturing company.

17

2.2.

Expression of hFGF-1

The expression vector pJExpress414 encoding the cDNA sequence of hFGF-1 was
performed following essential procedure. hFGF-1 cDNA was transformed into the host
cell Escherichia coli B21(DE3)pLysS for protein expression in high yields [67]. The
gene sequences were optimized using DNA2.0 codon bias algorithm to maximize the
yield of the proteins, prior to cloning [68].
Overnight 50 mL cultures of E. coli strain BL21(DE3)pLysS cells containing
recombinant plasmid were diluted into 1L cultures of Luria broth (LB) containing 100
µL/mL ampicillin and 35 µg/mL chloramphenicol and were incubated at 37°C at 150
rpm until the absorbance was 0.6 at 600nm. 1 mL of the uninduced sample was collected
at this point. Isopropylthio-ß-D-galactoside (IPTG) was then added to a final
concentration of 1.0 mM to induce the expression of the target protein. Again, 1 mL of
the induced sample was collected and the remaining cultures were collected by
centrifugation at 6000 rpm for 20 minutes. Cell pellets were then resuspended in 30 mL
1X PBS buffer. 1 mL sample was collected and the cells were lysed by ultrasonicator for
60 seconds at the power level of 15 Ohms and the lysate was cleared by centrifugation.
The expression of the protein (hFGF-1) was analyzed by SDS-PAGE. Protein samples of
both un-induced and induced cultures were centrifuged and the settled pellets were
dissolved in 8M urea followed by addition of 2X loading dye. The sample was then
centrifuged and 20 µL of the supernatant of each sample was added to each well in the
SDS gel and processed for 60 minutes at 180 Volts (Fig. 8).
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2.3.

Purification of hFGF-1

Human acidic fibroblast growth factor is a heparin binding protein. The binding
ability of hFGF-1 to heparin is retained even after deletion of the first 14 amino acids at
the N-terminal of the protein. The binding affinity of hFGF-1 to heparin facilitates the
purification of hFGF-1 from the cell crude lysate. The cells were harvested and lysed by
sonication. The lysate was then cleared by centrifugation at 12,000 rpm for 3 minutes.
The supernatant was then loaded on a heparin affinity column and incubated for 60
minutes. hFGF-1 was purified by applying a stepwise NaCl gradient from 0.0 M, 0.65
M, 0.85 M and 1.5 M NaCl in 10 mM phosphate buffer at pH 7.2 to the column. hFGF-1
was found to elute out at 1.5 M NaCl (Fig. 8). The proteins eluted at various
concentration of NaCl were analyzed by SDS-PAGE. The eluted protein was desalted in
the FPLC-size exclusion column.

19
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Figure 8: Schematic illustrating expression and purification of hFGF-1 in E.coli.

2.4.

Characterization of hFGF-1

The amino acid sequence of hFGF-1 is given in Table 2.
MFNLPPGNYK
KPKLLYCSNG
GHFLRILPDG

TVDGTRDRSD

QIQLQLSAES

VHGEVYIKST

ETGQYLAMDT

DGLLYGSQTP

NEECLFLERL

EENHYNTYIS

KKHAEKNWFV

GLKKNGSCKR

GPRTHYGQKA

ILFLPPLPVS

SD

Table 2: The various primary structural parameters of hFGF-1 were obtained using a
analysis tool called protparam.

hFGF-1 obtained with 1.5 M NaCl was further purified by gel filtration on Superdex
75 (Pharmacia) column by FPLC. Reverse phase HPLC was used to determine the purity
of hFGF-1. Electro-spray mass spectrum was also performed to confirm the exact
molecular weight of the purified protein. The yield of the purified hFGF-1 was
quantified using UV-Vis spectroscopy.

2.5.

Steady State Fluorescence

Fluorescence experiments were performed using PerkinElmer Spectro-fluorometer at
5 nm resolution. The excitation and emission wavelengths were set at 280 and 394 nm
respectively. Intrinsic fluorescence measurements were made at a protein concentration
of 50µM in presence of 50 µM of imatinib using an excitation wavelength of 280 nm.
The requisite temperature(s) in the thermal denaturation experiments was attained using
a Fisher thermo-scientific circulating water bath.
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2.6.

Proteolytic Digestion Assay

The limited proteolytic experiments on hFGF-1 and hFGF-1 - imatinib mixture (1:1)
were carried out (at 25 ± 2 °C) using trypsin. Trypsin was used as a protease for the
proteolytic digestion experiments. The trypsin digestion samples were collected at
desired time intervals. A ~16 kDa band was used as a control to measure the uncleaved
protein on SDS-PAGE.

2.7.

Surface Plasmon Resonance (SPR) Analysis

Binding analysis was performed using BIAcore X1000 instrument. Experiments
were performed at 25 °C with HBS-EP buffer (pH 7.4) as a running buffer and a flowrate of 20 µL/min. 10 µL of 25 µg/mL hFGF-1 in 1X HBS-EP buffer (pH 7.4) was used
for immobilization (ΔRU ~4000) on a CM5 chip. For hFGF-1 – imatinib interaction,
different concentrations of imatinib (6.25, 12.5, 25, 50 and 100 uM) in HBS-EP buffer
were injected over the hFGF-1 sensor chip for 180 seconds to observe the association
phase of the hFGF-1-imatinib interaction. After each analyte injection, HBS-EP buffer
was passed over the chip to monitor the dissociation phase. At the end of each sample
injection, the sensor surface was fully regenerated by injection of 20 µL of 2.5 M NaCl.
A sensorgram of binding of hFGF-1 to imatinib was plotted.
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3. RESULTS AND DISCUSSION
3.1.

Expression and Purification of hFGF-1
hFGF-1 used in the present study is a 154 amino acid polypeptide bereft of

disulfide bonds [69,70]. Gel electrophoresis experiments confirmed the presence of the
protein in soluble fraction of bacterial cell lysate. The purification was facilitated by
using heparin sepharose affinity chromatography to separate hFGF-1 from other
proteins. hFGF-1 was found to be bound to heparin quite strongly and the undesired
proteins and other materials such as lipids from the loaded lysate were removed by
extensively washing the resin with 10 mM phosphate buffer [71]. Purification was then
carried out over NaCl gradient (from 0 to 1.5 M) (Fig 9). Collected fractions were then
analyzed by SDS-PAGE. SDS-PAGE of the purified sample yielded an intense single
band corresponding to a molecular mass of ~16 kDa (Fig 10).
The yield of the purified hFGF-1 was quantified using UV-Vis spectroscopy and
found to be about 20-25 mg/L culture. hFGF-1 obtained with 1.5 M NaCl was further
purified by gel filtration on Superdex 75 (Pharmacia) column by FPLC (Fig. 11).
Reverse phase HPLC was used to determine the purity of the purified hFGF-1 (Fig.
12). The HPLC profile shows that the purified hFGF-1 is more than 95 %. The
molecular weights of the plain hFGF-1 estimated by ESI-Mass exactly matches with the
expected theoretical mass (Fig 13).
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Figure 9: Purification of hFGF-1 using sodium chloride gradient in heparin column.

Figure 10: SDS-PAGE depicting the expression and purification of hFGF-1 from E.coli.
Lane M, represents the molecular weight standards; Lane 1, un-induced bacterial cells;
Lane 2, induced bacterial cells; Lane 3, depicts soluble fraction; Lane 4, depicts
insoluble fraction. Lanes 5-12 represents the SDS-Page fractions collected with buffer
containing varying concentrations of sodium chloride. Lane 5, represents flow through;
Lane 6, depicts protein bands contained in fraction eluted in 10 mM phosphate buffer;
Lane 7, represents protein bands contained in fractions eluted in 0.8 M NaCl with 10
mM phosphate buffer; Lanes 8-11, depicts protein bands contained in fractions eluted in
10 mM phosphate buffer containing 1.5 M NaCl; Lane 12 depicts protein bands
contained in fraction eluted in 10 mM phosphate buffer.
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Figure 11: Size-exclusion chromatography profile of hFGF-1 using FPLC at room
temperature. The elution time was 74.5 ± 0.5 mins.

Figure 12: Reverse phase HPLC profile for purified hFGF-1. Protein was eluted at
~33.56 mins in a water and acetonitrile gradient.
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Figure 13: Electron-spray mass spectrum of hFGF-1 shows expected molecular weight
of hFGF-1 (15.967 kDa).
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3.2.

hFGF-1 is Stabilized by Imatinib Binding

3.2.1. Steady State Fluorescence
hFGF-1 contains a single well conserved tryptophan at position 121 [72]. The
aromatic amino acid tyrosine shows the emission peak at 308 nm when hFGF-1 is in
native state [71,73,74]. However, when the protein is in denatured state, tryptophan peak
is dominated at 350 nm [71,74]. These fluorescence features can be used to monitor the
thermal denaturant unfolding of hFGF-1 (Fig. 14). Equilibrium thermal denaturation of
hFGF-1 was performed to assess the conformational stability of hFGF-1 upon binding to
imatinib (Fig. 15). The Tm (the temperature at which 50% of the molecules are in the
native state) of the protein increases in the presence of the drug by about 6 °C (from 51
°C to 57 °C), suggesting that thermodynamic stability of the protein is enhanced upon
binding to the drug.
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Figure 14: Represents the emission spectra of hFGF-1 in its native (green) and
denatured (red) states. Ratio of intensities 308/350: ~4 for native, properly folded and
~1 for altered structure.

Figure 15: Represents the thermal unfolding of hFGF-1 in the absence (red) and in the
presence (blue) of imatinib. The Tm (melting temperature of protein) value of the
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thermal induced unfolding of hFGF-1 estimated
from the fluorescence experiment is
51⁰C in the absence and 57 ⁰C in the presence of imatinib.

3.2.2. Proteolytic Digestion
Limited proteolytic digestion is a popular technique to probe the protein-ligand
interactions [75]. In principle, binding of a ligand/drug can potentially mask the
cleavage sites in the protein substrate and these subtle differences in the cleavage
patterns (between the free and the ligand/drug bound protein substrate) could be easily
detected by SDS-PAGE analysis [75–77]. As hFGF-1 contains lots of arginine and
lysine residues, we plan to determine the binding of imatinib to hFGF-1 using a limited
trypsin technique. The experiment was carried out for hFGF-1 and the hFGF-1-imatinib
mixture at 25 ± 2 °C using trypsin in a time-dependent manner. The uncleaved hFGF-1
was measured using SDS-PAGE by comparing with the parent band intensity. SDSPAGE analysis of the tryptic digests of hFGF-1 obtained in the presence and absence of
imatinib clearly reveals that the protein upon binding to the drug is more resistant to
proteolytic cleavage (Fig. 16). The enhanced resistance of trypsin cleavage could be due
to masking of some of the potential enzyme cleavage sites in hFGF-1 by imatinib.
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Figure 16: Limited trypsin digestion monitored by SDS-PAGE of hFGF-1 in the
absence of (A) and presence (B) of imatinib. Lane C contained hFGF-1 in the absence
of trypsin. Lanes 0-80 contained the trypsin digestion cleavage products obtained at
various time periods of incubation with trypsin in the absence and presence of imatinib.
It could be observed that the protein in the presence of imatinib is more resistant to
trypsin cleavage.
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3.2.3. Surface Plasmon Resonance (SPR)
Biacore is a technique that monitors molecular interactions in real time by measuring
surface binding of unlabeled drug to protein-coated surfaces [78,79]. It responds to
changes in the concentration of molecules at a sensor surface as molecules bind to or
dissociate from the surface. The binding of the ligand is detected by an optical
phenomenon called surface plasmon resonance (SPR). In this case, we assessed the
binding affinity of imatinib to hFGF-1, by analyzing the level of steady state response
against concentration. The interactions are monitored on a CM5 chip. A glass slide
coated with thin gold film creates a surface sensor. Dextran acts as a substrate to which
hFGF-1 was immobilized and provides a hydrophilic environment for the interaction.
Varying concentrations of imatinib (drug) was injected on a continuous flow of solution.
SPR causes a reduction in the intensity of light reflected at a specific angle from the
glass side of the sensor surface. As molecules binds to the sensor surface, the refractive
index close to the surface changes. This change in SPR angle is directly proportional to
the change in mass concentration of the material bound [78,79]. The kon and koff rates
were measured to calculate the dissociation constant (Kd). Using the result from the
change in refractive index, a sensorgram with binding response on y-axis and time in
seconds on x-axis was plotted. As appears from Fig. 17, imatinib at varying
concentrations was capable of strongly binding to hFGF-1 which is in agreement with
proteolytic digestion and thermal denaturation studies. The Kd was found to be 6.9 M
and it was further confirmed by repeating the experiments. However Kd of 6.9 M is too
large for a strong binding and it is unreliable too. And also the kon and koff rates are too
fast for the instrument to detect and therefore the Kd value might be incorrect. The
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detectable kon range for biacore is 103- 107 M-1s-1 and for koff the range is 10-5- 10-1 s-1.
This means the Biacore instrument cannot detect such quick/strong interaction and
therefore cannot give us accurate Kd. But results clearly suggest that imatinib binds with
hFGF-1 under the experimental conditions quickly and strongly.
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Figure 17: Representative measurements of imatinib binding to hFGF-1: (A) SPR
sensorgrams showing the change in binding response (in RU) upon injection of various
concentrations of imatinib from 6.25 µM to 100 µM in HBS-EP buffer over hFGF-1
surface; (B) binding curve constructed by plotting the observed binding response against
imatinib concentrations.
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4. CONCLUSION
Human Fibroblast growth factor-1 was successfully expressed and purified in higher
yield from bacterial E. coli expression system using affinity chromatography and
dialysis techniques. Purity and authenticity of the protein was further confirmed by
SDS-Gel electrophoresis, steady state fluorescence, fast liquid chromatography, and LCMS. Results of these studies clearly suggest the purified protein is pure and in its native
confirmation. Interaction studies such as, thermal unfolding and proteolytic digestion of
hFGF-1 in the presence imatinib were conducted. Control experiments without the use
of ligand were also carried out in order to evaluate the changes in the stability of protein
in the presence of ligand. In the thermal unfolding experiment, intrinsic fluorescence
spectra of hFGF-1 were obtained from 20 ºC to 80 ºC. The Tm of hFGF-1 in the presence
of imatinib was increased by about 6 ºC. In limited trypsin digestion experiment, where
the hFGF-1 was subjected digestion with protease trypsin, hFGF-1 showed more
resistance to trypsin in the presence of ligand compared to control. Results of this
studies confirmed that imatinib binds strongly with hFGF-1 and increase its thermal
stability and solvent accessibility. In order to further investigate the binding affinity
between the imatinib and hFGF-1, Biacore, a surface plasmon resonance experiment
was performed. Results of this study clearly suggest imatinib binds very strongly with
hFGF-1. The findings of the present study will facilitate research towards understanding
the hFGF-1 induced angiogenesis. The information acquired from this study will also be
of substantial use for developing various drugs having structure resemblance to imatinib
against growth factors.
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5. FUTURE WORK
The finding that imatinib binds tights with hFGF-1 provides valuable clues for the
rational design of novel pharmacological approaches to the treatment of inflammatory,
cardiovascular and oncological disorder. Further binding experiments such as isothermal
titration calorimetry (ITC) is essential to characterize the dissociation constant, enthalpy
change of interaction. ITC experiments can be extended to test the competition studies
between the imatinib against heparin and FGFR, which is very critical to evaluate the
inhibitory action of hFGF-1 signaling by imatinib. Structural studies always play an
important role in any drug design. In this context, structural studies are required
including multi-dimensional nuclear magnetic experiments are required to in order to
characterize the binding site of imatinib on hFGF-1 and also able to solve the hFGF-1 imatinib binary complex structure. In addition, in vivo experimental studies on hFGF-1
interaction with imatinib will give information about possibility of interaction under
physiological conditions. Therefore, the future work will give more insight into the
interaction between imatinib and hFGF-1, results will give further leads in to anticancer
activity of imatinib.
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7. ABBREVIATIONS
AB

Acid Box

E.coli

Escherichia coli

ER

Endoplasmic Reticulum

ESI-MS

Electro-Spray Ionization Mass Spectrometry

FGFR

Fibroblast Growth Factor Receptor

FPLC

Fast Performance Liquid Chromatography

hFGF

Human Fibroblast Growth Factor

HPLC

High Performance Liquid Chromatography

HSPG

Heparin Sulfate Proteoglycans

IPTG

Isopropyl β-D-1-thiogalactopyranoside

ITC

Isothermal Titration Calorimetry

Kd

Dissocation Rate Constant

L.B

Luria Broth

NaCl

Sodium Chloride

NLS

Nuclear Localization Sequence

NMR

Nuclear Magnetic Resonance

RU

Response Units

SDS-PAGE Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis
SPR

Surface Plasmon Resonance

Syt1

Synaptotagmin

TCA

2,4,6-Trichloroanisole

TM

Transmembrane
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